نتایج جستجو برای: rhuepo
تعداد نتایج: 367 فیلتر نتایج به سال:
Problem statement: Erythropoietin receptor (EPOR) has been detected in breast cancer cells and speculated to be involved in cancer growth, viability and angiogenesis. This has risen suspicious that EPO administration may enhance the severity of cancer. Approach: This study was undertaken to determine the effects of rHuEPO, Tamoxifen and their combination on the growth and angiogenesis of mammar...
OBJECTIVE The efficacy and safety of recombinant human erythropoietin (rHuEPO) treatment in chemotherapy-induced anemia in children were investigated. rHuEPO is used to treat chemotherapy-induced anemia. Several studies recommend 150 to 300 IU/kg rHuEPO for 2 to 8 months. There are only a few controlled trials in children and no precise data about the optimal dose and duration of rHuEPO treatme...
BACKGROUND A number of anaemic cancer patients are not responsive to treatment with recombinant human erythropoietin (rHuEPO). The aim of the present study is to investigate whether serum levels of tumour necrosis factor-alpha (TNF-alpha), interleukin (IL)-1beta, IL-6 and additional laboratory parameters, together with clinical variables, can predict the clinical outcome of treatment with rHuEP...
We have used recombinant human erythropoietin (rHuEPO) in a phase I/II clinical trial to evaluate its ability to reverse refractory anemia in hematologic disorders. rHuEPO was administered subcutaneously 5 days per week at escalating doses (50 to 150 U/kg per day). The aim of treatment was a hemoglobin (Hb) level greater than or equal to 10 g/dL without blood transfusion. Of 25 patients treated...
Erythropoietin (rHuEPO) has proven to be effective in the treatment of anemia of chronic renal failure (CRF). Despite improving the quality of life, peak oxygen uptake after rHuEPO therapy is not improved as much as the increase in hemoglobin concentration ([Hb]) would predict. We hypothesized that this discrepancy is due to failure of O 2 transport rates to rise in a manner proportional to [Hb...
recombinant human erythropoietin is a glycoprotein hormone that stimulates erythropoiesis. in clonogenic assays of hematopoietic progenitors, high concen-trations of erythropoietin (epo) increase cfu-e and diminish the number of granulocytes formed per culture plate. fetal progenitors are more sensitive to these effects of epo than progenitors from adults. we administered doses 50, 100, 200 iu/...
The majority of patients with chronic kidney disease are anaemic. Iron deficiency should be corrected before treatment with recombinant human erythropoietin (rhuEpo) or novel erythropoiesis stimulating protein (NESP) is initiated. During maintenance rhuEpo or NESP therapy, iron supplementation is needed to prevent hyporesponsiveness to these drugs. On the other hand, iron supplementation is not...
Combined therapy with amifostine plus erythropoietin for the treatment of myelodysplastic syndromes.
Twelve patients with myelodysplasia were treated with amifostine plus recombinant human erythropoietin (rHuEpo) for 6 weeks. A complete erythroid response was obtained in 2/12(16.6%) and a partial response in 4/12 (33.3%). Two of 8 patients with a platelet count < 100 x 10(9)/L had a complete response, as did 3/9 with a neutrophil count < 1.5 x 10(9)/L. Compared to rHuEpo or amifostine used as ...
Anaemia is a common problem in end stage kidney disease. Recombinant human erythropoietin (rHuEPO) is commonly used in management of such patients to maintain optimal hemoglobin levels and to minimise transfusion requirements. Acquired pure red cell aplasia (PRCA) is a rare complication of erythropoietin therapy due to development of anti-erythropoietin antibodies (anti-EPOabs). We report a pat...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید